Clinical Trial Update: Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of Varlitinib plus Capecitabine for advanced or metastatic biliary tract cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Varlitinib (varlitinib)

Snippet

Sponsor: ASLAN Pharmaceuticals | Conditions: Advanced or Metastatic Biliary Tract Cancer | Phase 2 | Status: WITHDRAWN